Literature DB >> 24440055

Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease.

Meredith A Chabrier1, David Cheng1, Nicholas A Castello1, Kim N Green1, Frank M LaFerla2.   

Abstract

Synapse number is the best indicator of cognitive impairment In Alzheimer's disease (AD), yet the respective contributions of Aβ and tau, particularly human wild-type tau, to synapse loss remain undefined. Here, we sought to elucidate the Aβ-dependent changes in wild-type human tau that trigger synapse loss and cognitive decline in AD by generating two novel transgenic mouse models. The first overexpresses floxed human APP with Swedish and London mutations under the thy1 promoter, and recapitulates important features of early AD, including accumulation of soluble Aβ and oligomers, but no plaque formation. Transgene excision via Cre-recombinase reverses cognitive decline, even at 18-months of age. Secondly, we generated a human wild-type tau-overexpressing mouse. Crossing of the two animals accelerates cognitive impairment, causes enhanced accumulation and aggregation of tau, and results in reduction of dendritic spines compared to single transgenic hTau or hAPP mice. These results suggest that Aβ-dependent acceleration of wild-type human tau pathology is a critical component of the lasting changes to dendritic spines and cognitive impairment found in AD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dendritic spines; Transgenic; Wild-type tau

Mesh:

Substances:

Year:  2014        PMID: 24440055      PMCID: PMC4072239          DOI: 10.1016/j.nbd.2014.01.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  33 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau.

Authors:  Dara L Dickstein; Hannah Brautigam; Steven D Stockton; James Schmeidler; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-03-07       Impact factor: 3.270

5.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 6.  Overexpression of growth-associated proteins in the neurons of adult transgenic mice.

Authors:  P Caroni
Journal:  J Neurosci Methods       Date:  1997-01       Impact factor: 2.390

7.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

8.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

9.  Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

Authors:  Jeannie Chin; Jorge J Palop; Gui-Qiu Yu; Nobuhiko Kojima; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

10.  Soluble aβ promotes wild-type tau pathology in vivo.

Authors:  Meredith A Chabrier; Mathew Blurton-Jones; Andranik A Agazaryan; Joy L Nerhus; Hilda Martinez-Coria; Frank M LaFerla
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

View more
  43 in total

1.  Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model.

Authors:  Haley C Dunn; Rahasson R Ager; David Baglietto-Vargas; David Cheng; Masashi Kitazawa; David H Cribbs; Rodrigo Medeiros
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease.

Authors:  Alejandro Uribe-Arias; Rafael Andrés Posada-Duque; Christian González-Billault; Andrés Villegas; Francisco Lopera; Gloria Patricia Cardona-Gómez
Journal:  J Neurochem       Date:  2016-07-05       Impact factor: 5.372

Review 3.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

Review 4.  Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.

Authors:  Ke Li; Qing Wei; Fang-Fang Liu; Fan Hu; Ao-Ji Xie; Ling-Qiang Zhu; Dan Liu
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

Review 5.  Do Sleep Disturbances have a Dual Effect on Alzheimer's Disease?

Authors:  Shirin Arjmandi-Rad; Mahshid Ebrahimnejad; Mohammad-Reza Zarrindast; Salar Vaseghi
Journal:  Cell Mol Neurobiol       Date:  2022-05-14       Impact factor: 5.046

6.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

7.  Increased tauopathy drives microglia-mediated clearance of beta-amyloid.

Authors:  Wesley Chen; Edsel A Abud; Stephen T Yeung; Anita Lakatos; Trevor Nassi; Jane Wang; David Blum; Luc Buée; Wayne W Poon; Mathew Blurton-Jones
Journal:  Acta Neuropathol Commun       Date:  2016-06-23       Impact factor: 7.801

Review 8.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

Review 9.  Amyloid-β: a potential link between epilepsy and cognitive decline.

Authors:  Michele Romoli; Arjune Sen; Lucilla Parnetti; Paolo Calabresi; Cinzia Costa
Journal:  Nat Rev Neurol       Date:  2021-06-11       Impact factor: 42.937

Review 10.  Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.

Authors:  Bin-Lu Sun; Yang Chen; Dong-Yu Fan; Chi Zhu; Fan Zeng; Yan-Jiang Wang
Journal:  Sci China Life Sci       Date:  2020-10-23       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.